RARE Relative Valuation
RARE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RARE is overvalued; if below, it's undervalued.
Historical Valuation
Ultragenyx Pharmaceutical Inc (RARE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.07 is considered Undervalued compared with the five-year average of -9.02. The fair price of Ultragenyx Pharmaceutical Inc (RARE) is between 38.50 to 106.45 according to relative valuation methord. Compared to the current price of 22.54 USD , Ultragenyx Pharmaceutical Inc is Undervalued By 41.46%.
Relative Value
Fair Zone
38.50-106.45
Current Price：22.54
41.46%
Undervalued
-4.95
PE
1Y
3Y
5Y
-7.13
EV/EBITDA
Ultragenyx Pharmaceutical Inc. (RARE) has a current EV/EBITDA of -7.13. The 5-year average EV/EBITDA is -9.49. The thresholds are as follows: Strongly Undervalued below -19.26, Undervalued between -19.26 and -14.38, Fairly Valued between -4.60 and -14.38, Overvalued between -4.60 and 0.29, and Strongly Overvalued above 0.29. The current Forward EV/EBITDA of -7.13 falls within the Historic Trend Line -Fairly Valued range.
-6.16
EV/EBIT
Ultragenyx Pharmaceutical Inc. (RARE) has a current EV/EBIT of -6.16. The 5-year average EV/EBIT is -9.14. The thresholds are as follows: Strongly Undervalued below -17.93, Undervalued between -17.93 and -13.53, Fairly Valued between -4.75 and -13.53, Overvalued between -4.75 and -0.35, and Strongly Overvalued above -0.35. The current Forward EV/EBIT of -6.16 falls within the Historic Trend Line -Fairly Valued range.
3.07
PS
Ultragenyx Pharmaceutical Inc. (RARE) has a current PS of 3.07. The 5-year average PS is 9.72. The thresholds are as follows: Strongly Undervalued below -1.85, Undervalued between -1.85 and 3.93, Fairly Valued between 15.50 and 3.93, Overvalued between 15.50 and 21.28, and Strongly Overvalued above 21.28. The current Forward PS of 3.07 falls within the Undervalued range.
-6.08
P/OCF
Ultragenyx Pharmaceutical Inc. (RARE) has a current P/OCF of -6.08. The 5-year average P/OCF is -3.04. The thresholds are as follows: Strongly Undervalued below -83.77, Undervalued between -83.77 and -43.41, Fairly Valued between 37.33 and -43.41, Overvalued between 37.33 and 77.70, and Strongly Overvalued above 77.70. The current Forward P/OCF of -6.08 falls within the Historic Trend Line -Fairly Valued range.
71.87
P/FCF
Ultragenyx Pharmaceutical Inc. (RARE) has a current P/FCF of 71.87. The 5-year average P/FCF is -25.83. The thresholds are as follows: Strongly Undervalued below -593.23, Undervalued between -593.23 and -309.53, Fairly Valued between 257.87 and -309.53, Overvalued between 257.87 and 541.57, and Strongly Overvalued above 541.57. The current Forward P/FCF of 71.87 falls within the Historic Trend Line -Fairly Valued range.
Ultragenyx Pharmaceutical Inc (RARE) has a current Price-to-Book (P/B) ratio of 248.06. Compared to its 3-year average P/B ratio of 51.51 , the current P/B ratio is approximately 381.61% higher. Relative to its 5-year average P/B ratio of 33.09, the current P/B ratio is about 649.60% higher. Ultragenyx Pharmaceutical Inc (RARE) has a Forward Free Cash Flow (FCF) yield of approximately -19.86%. Compared to its 3-year average FCF yield of -14.29%, the current FCF yield is approximately 38.97% lower. Relative to its 5-year average FCF yield of -11.89% , the current FCF yield is about 67.07% lower.
248.06
P/B
Median3y
51.51
Median5y
33.09
-19.86
FCF Yield
Median3y
-14.29
Median5y
-11.89
Competitors Valuation Multiple
The average P/S ratio for RARE's competitors is 9.11, providing a benchmark for relative valuation. Ultragenyx Pharmaceutical Inc Corp (RARE) exhibits a P/S ratio of 3.07, which is -66.3% above the industry average. Given its robust revenue growth of 14.65%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RARE decreased by 47.62% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -95.71 to -112.81.
The secondary factor is the Revenue Growth, contributed 14.65%to the performance.
Overall, the performance of RARE in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
WMT
Walmart Inc
112.72USD
-1.42%
AMZN
Amazon.com Inc
241.56USD
0.26%
GOOGL
Alphabet Inc
321.98USD
2.43%
META
Meta Platforms Inc
648.69USD
-1.81%
NVDA
NVIDIA Corp
189.11USD
1.00%
MSFT
Microsoft Corp
483.47USD
1.04%
AVGO
Broadcom Inc
343.5USD
-0.08%
TSLA
Tesla Inc
431.41USD
-0.36%
GOOG
Alphabet Inc
322.43USD
2.51%
AAPL
Apple Inc
260.33USD
-0.77%
Frequently Asked Questions
Is Ultragenyx Pharmaceutical Inc (RARE) currently overvalued or undervalued?
Ultragenyx Pharmaceutical Inc (RARE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.07 is considered Undervalued compared with the five-year average of -9.02. The fair price of Ultragenyx Pharmaceutical Inc (RARE) is between 38.50 to 106.45 according to relative valuation methord. Compared to the current price of 22.54 USD , Ultragenyx Pharmaceutical Inc is Undervalued By 41.46% .
What is Ultragenyx Pharmaceutical Inc (RARE) fair value?
RARE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Ultragenyx Pharmaceutical Inc (RARE) is between 38.50 to 106.45 according to relative valuation methord.
How does RARE's valuation metrics compare to the industry average?
The average P/S ratio for RARE's competitors is 9.11, providing a benchmark for relative valuation. Ultragenyx Pharmaceutical Inc Corp (RARE) exhibits a P/S ratio of 3.07, which is -66.30% above the industry average. Given its robust revenue growth of 14.65%, this premium appears unsustainable.
What is the current P/B ratio for Ultragenyx Pharmaceutical Inc (RARE) as of Jan 07 2026?
As of Jan 07 2026, Ultragenyx Pharmaceutical Inc (RARE) has a P/B ratio of 248.06. This indicates that the market values RARE at 248.06 times its book value.
What is the current FCF Yield for Ultragenyx Pharmaceutical Inc (RARE) as of Jan 07 2026?
As of Jan 07 2026, Ultragenyx Pharmaceutical Inc (RARE) has a FCF Yield of -19.86%. This means that for every dollar of Ultragenyx Pharmaceutical Inc’s market capitalization, the company generates -19.86 cents in free cash flow.
What is the current Forward P/E ratio for Ultragenyx Pharmaceutical Inc (RARE) as of Jan 07 2026?
As of Jan 07 2026, Ultragenyx Pharmaceutical Inc (RARE) has a Forward P/E ratio of -4.95. This means the market is willing to pay $-4.95 for every dollar of Ultragenyx Pharmaceutical Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Ultragenyx Pharmaceutical Inc (RARE) as of Jan 07 2026?
As of Jan 07 2026, Ultragenyx Pharmaceutical Inc (RARE) has a Forward P/S ratio of 3.07. This means the market is valuing RARE at $3.07 for every dollar of expected revenue over the next 12 months.